

ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES

# BIO-GENE TECHNOLOGY LIMITED

11 AUGUST 2023

FY23 Business Update

PRESENTED BY

Richard Jagger

CEO

Rod Valencia

CFO & Co. Sec.



BIO-GENE  
TECHNOLOGY  
LTD



# DISCLAIMER

This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitation in respect of securities in the Company. No agreement to subscribe for securities will be entered into on the basis of this presentation or any information contained in this presentation.

This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of another jurisdiction. This presentation is provided for general information purposes only and is selective, does not purport to contain all relevant information and has not been independently verified.

Neither the Company nor its advisors have any responsibility or obligation to inform any recipient of any matter arising or coming to their notice after the date of this presentation, which may affect any matter referred to in the presentation. The Company releases material information as announcements to the ASX (ASX:BGT). Recipients seeking further information in respect of the Company should review the Company's announcements as released to ASX from time to time.

Nothing in this presentation constitutes investment, legal, tax, accounting or other advice. The recipient should consider its own financial situation, objectives and needs and conduct its own independent investigation and assessment, including obtaining investment, legal, tax, accounting or other advice as it considers necessary or appropriate.

The distribution of this presentation (including electronic copies) outside Australia may be restricted by law and persons who come into possession of this presentation outside Australia should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

This presentation may contain statements relating to intentions, future acts and events (Forward Looking Statements). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed. No representation, warranty or guarantee, express or implied, is given that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable.

No financial information (unless also contained in financial reports released to ASX), estimates or projections contained in this presentation or as derived from such financial information, estimates or projections can be relied upon as a promise or representation as to any present or future matter.

To the maximum extent permitted by law, neither the Company nor any of its associates, directors, officers, employees, advisors or representatives make any representation or provide any warranty, express or implied, as to the accuracy, reliability or completeness of the information contained in this presentation or any subsequent information provided to the recipient including, but not limited to, any financial projections, estimates or other historical information.

Any statement made in or during the course of this presentation relating to efficacy, market segments, fields of use, products, applications or synergy is to be taken in context of the disclosures made in published patent applications owned by the Company, a list of which may be provided upon request, and the disclosure of each of which is hereby incorporated by reference in its entirety.



---

# AGENDA

- Bio-Gene Business Overview
- Performance Highlights
- Operational Update
- FY23 Financials
- Outlook
- Q&A



# GLOBAL CHALLENGES AND RESISTANT PEST CONTROL

## Food Security & Public Health

- Growing population = more food
- Climate change = more mosquitos

## Financial Impact

- Production lost to pests = higher costs, lost income
- Direct & economic impact of disease

## Social Impact

- Vector borne disease = increased risk to more humans
- More people = less arable land



“Without Crop Protection, crop losses would double each year”

CropLife




“No new public health insecticides have been developed for mainstream vector control for 30 years”

CDC

# BIO-GENE'S CHEMISTRY IS A STEP-CHANGE FOR RESISTANT PEST CONTROL

- **Novel Mode of Action (MoA)**
  - Last new MoA commercialised in 2008, with current sales of US\$2.3bn
- **Naturally derived and safe chemistry**
- **Efficacy across a number of target pests**
- **Addresses multiple market segments**
  - Crop protection, grain storage, consumer applications, public health & animal health
- **Third Party Validation**
  - Multiple commercial deals with industry leading companies
- **Multiple revenue streams**
  - Licensing fees, milestone payments, active ingredient supply, royalties



## Qcide™

### Natural Compound

An extract of a specific cultivar of eucalypt, the Gypmie Messmate

Trees farmed in QLD

The leaves contain oil expressing high levels of Tasmanone,



## Flavocide™


### Nature Identical Compound

Active ingredient Flavesone is found in Nature

Synthesised via new proprietary process

Can be produced in large volumes globally

# BIO-GENE'S PRODUCTS TARGET 5 KEY MARKET SEGMENTS




# FY23 PERFORMANCE HIGHLIGHTS

Key developments achieved in FY23 collectively pave a clear path towards commercialisation


## FY23 Key Achievements




## US\$31.1 billion Addressable Market



## Key Achievements subsequent to year end







# OPERATIONAL UPDATE





# STRATEGY

## Commercialisation pathway

- Active ingredient registrations
- Product development, marketing & distribution with strong commercial partners
- Developing additional IP, proprietary manufacturing & production know-how


## Revenue drivers

- Technology licensing fees
- Milestone payments
- Active ingredient supply
- Royalties

# REVENUE PROFILE EXPECTATIONS

## FY 2023


- ✓ Registration and Commercial development stage
- ✓ Licence fees, milestone payments and raw materials part support capital needs
- ✓ Critical phase of commercial development supporting future high margin royalty stream future



■ Licence Fees

## FY 2027


- ✓ Active ingredients first registrations
- ✓ Products developed can go to market



■ Milestone

## FY 2031

- ✓ Expanding commercialised product driving significant increase in royalty payments
- ✓ High margins



■ Raw Materials

■ Royalty

# COMMERCIAL PARTNERSHIP SNAPSHOT

Additional opportunities with other commercial partners advancing



**STK applies advanced botanical science and bio-ag technology in the development & commercialisation of natural crop protection for growers worldwide**

Develop, register and commercialise Qcide for crop protection

- ✓ STK will fully fund the registration
- ✓ Bio-Gene has full registration access

## Revenue Model

Active ingredient supply to STK

On-going royalties on end use product sales with other commercial partners



**Clarke is the largest vertically integrated company in public health mosquito control**

Develop, register and commercialise Flavocide for public health and residential mosquito control in US and Caymen Islands

- ✓ Clarke will fully fund registration of end use products
- ✓ \$250m total addressable market

## Revenue Model

Up-front licence fee

Milestone payments prior to registration

On-going royalties on end-use product sales

Development costs borne by Clarke



**Evergreen is a market leader in consumer products across Europe and in Australia/New Zealand**

Develops and registers products for consumer applications across Europe, UK, Australia and NZ

- ✓ Additional field work aligned to European summer

## Revenue Model

Up-front licence fee

Milestone payments prior to registration

On-going royalties on end-use product sales

Development costs borne by Evergreen





**Our key and expanding commercial partnerships position us for significant commercial success.**

**– Richard Jagger**  
**MD & CEO**



# COMMERCIAL FY23 ADVANCEMENT SUMMARY

Commercial partnerships and third-party validation are critical for our business progression

Partnership	Advancement Made	Value Add
STK 	Completion of STK agreement for Qcide	<ul style="list-style-type: none"><li>✓ STK fully funds multi-million dollar Qcide registration cost</li><li>✓ BGT retains full commercial flexibility</li><li>✓ Enables BGT to work with all commercial partners in all key markets for Qcide</li></ul>
Clarke 	Clarke market extension	<ul style="list-style-type: none"><li>✓ Significant expansion of market opportunity across the United States</li></ul>
GRDC 	GRDC confirmation of support for grain storage program	<ul style="list-style-type: none"><li>✓ Supports conversations with potential commercial partners</li><li>✓ Leverage knowledge (industry &amp; regulatory processes)</li><li>✓ Future support of development programs</li></ul>
Evergreen 	Additional formulation evaluation underway	<ul style="list-style-type: none"><li>✓ Confirming efficacy at a field level</li></ul>

# OPERATIONAL ADVANCEMENTS

Intellectual property advancements are critical to the value of BGT to our customers



## Synergy leads to new partner evaluation

- Significant opportunity to reduce insecticide load, address resistance, reduce cost & support post-patent strategies for partners.
- Opens broader market possibilities



## CDC funded program on ticks

- US Government funded, aims to demonstrate fit with tick control (vector)



## Two new patents granted

- Significant coverage across the United States in all markets (US\$5B market)




## Developments in manufacturing partnerships

- Refining cost and safety of manufacture – developing Intellectual Property

# LEADERSHIP TEAM EVOLVES FOR NEXT STAGE OF GROWTH

- Appointment of Alex Ding as Chair upon retirement of Robert Klupacs
- Appointment of Tim Grogan as new CEO
- Richard Jagger focusing on commercial partnerships
- Follows on from:
  - Appointment of Chris Ramsay as new Non-Executive Director
  - Appointment of Rod Valencia as CFO / Co Sec / Investors Relations





# FY23 FINANCIALS



# FINANCIAL UPDATE – KEY METRICS

AUD (\$'000)	FY22	FY23
Revenue	446	149
Other income	493	532
Reported Net Loss	(2,914)	(3,096)
	FY22	FY23
Net Cash Used in Operations	(1,993)	(3,276)
Cash	6,342	2,991

- FY23 Commentary
  - Revenue includes milestone payments \$150k
  - Other income includes R&D refund ~\$440k per year
  - Net cash Used in Operations included:
    - R&D expense \$2m
    - Intellectual Property and patent registrations \$300k
    - Commercial expenses \$300k
    - Administrative expenses \$1.2m
  - Cash position of ~\$3.0m with no bank debt

# COMMERCIALISATION PATHWAY AND CAPITAL INTENSITY

Commercialisation Pathway	Current Initiatives	Capital Intensity
<ul style="list-style-type: none"> <li>Active ingredient registrations</li> </ul>	<ul style="list-style-type: none"> <li>Investment to register active ingredient significant</li> <li>STK deal (significant financial upside for BGT)</li> <li>Focused on Flavocide registration</li> </ul>	<ul style="list-style-type: none"> <li>Qcide registration – no (minimal) cost</li> <li>Capital intensity – becoming high with registration study commitments for Flavocide</li> </ul>
<ul style="list-style-type: none"> <li>Product development, Marketing &amp; distribution with strong commercial partners</li> </ul>	<ul style="list-style-type: none"> <li>Initiate STK deal after signing</li> <li>Advance other commercial partnerships</li> <li>Undertake further supportive efficacy studies</li> </ul>	<ul style="list-style-type: none"> <li>Capital intensity – low to medium</li> </ul>
<ul style="list-style-type: none"> <li>Developing additional IP, proprietary manufacturing &amp; production know-how</li> </ul>	<ul style="list-style-type: none"> <li>Further refinement of Flavocide / Qcide processes (cost reductions)</li> <li>Combination (synergy) IP</li> <li>Finalising Flavocide manufacturing partnership agreements</li> </ul>	<ul style="list-style-type: none"> <li>Capital intensity – medium</li> </ul>





# OUTLOOK



# OUTLOOK

- Additional synergy/efficacy testing
- Advance other commercial partnerships
- Deliver manufacturing partnerships
- Advance our regulatory applications with governing bodies
- Continue to advance our business model via licences, milestones, active ingredient sales & royalties



ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES

# BIO-GENE TECHNOLOGY LIMITED

Q&A

20  
23

BIO-GENE  
TECHNOLOGY  
LTD

